• According to the American Cancer Society (ACS) bladder cancer is the 4th most common cancer in men;
  • In 2023, the ACS estimates About 82,290 new cases of bladder cancer (about 62,420 in men and 19,870 in women) and about 16,710 death from bladder cancer;
  • Bladder cancer is suspected in patients with blood in the urine (hematuria), frequent and/or painful urination, and lower back/pelvic pain;
  • Bladder cancer is commonly detected and diagnosed at more advanced stages (II-IV) of disease and many patients with the early stages may be asymptomatic;
  • Definitive diagnosis is usually accomplished by radiographic imaging (CT) and invasive cystoscopy (see below);
  • Bladder cancer is among the most costly forms of cancer to treat. It may recur after treatment and it may even progress if not cured;
  • By the time bladder cancer is detected, it may be serious and can be progressive; our Rametrix® Molecular Urinalysis System offers an innovative approach to detection and management of bladder cancer.

Click here for additional information.